Business and industry articles within Nature Chemistry

Featured

  • Q&A |

    Gemma Tracey talks to Nature Chemistry about ingrained inequalities in the research community and the role of funders in replacing privilege with equitable and transparent systems.

    • Anne Pichon

  • Q&A |

    The career paths of Alveda Williams and Cory Valente have closely mirrored each other — perhaps surprisingly so for a straight Black woman and a gay white man with very different childhoods. They talk to Nature Chemistry about their journeys from research and development roles to Dow’s inclusion and diversity team.

    • Anne Pichon

  • Comment |

    The gap between fundamental academic research and the applied industrial research that is necessary to ensure real-world applications can be bridged by engaging in well-defined collaborative academia–industry projects and fostering better communication between the scientists involved in them.

    • Danielle Schultz
    •  & Louis-Charles Campeau

  • Editorial |

    Taking chemical technology from the bench to the consumer is a formidable challenge, but it is how research can ultimately benefit wider society. Companies are now beginning to incorporate metal–organic frameworks into commercial products, heralding a new era for the field.

  • Interview |

    Omar Farha (Chief Science Officer & technical founder) and Ben Hernandez (Chief Executive Officer) of NuMat Technologies, talk to Nature Chemistry about the release of one of the first MOF-based commercial products and the challenges the journey posed.

    • Thomas Faust

  • Thesis |

    Chemical compounds are often taken for granted, argues Bruce Gibb, and the most underappreciated is one that we're all very familiar with.

    • Bruce C. Gibb

  • Commentary |

    Changes in the chemical industry over the past decade — ranging from globalization to an increased focus on speciality chemicals — threaten to leave the aspiring industrial chemist unprepared. This Commentary discusses those changes and outlines strategies to enter the job market as well equipped as possible.

    • Keith J. Watson

  • Editorial |

    Cuts in pharmaceutical R&D jobs might provide short-term improvements to the bottom line, but do not bode well for the industry in the long run.

Browse broader subjects

Browse narrower subjects

Browse Business and industry across other nature.com journals